)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Hua Medicine (2552) investor relations material
Hua Medicine H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary29 Aug, 2025
Executive summary
Achieved 112% year-over-year revenue growth in H1 2025, reaching RMB 217.4 million, driven by full self-commercialization of HuaTangNing and expanded hospital coverage after regaining rights from Bayer.
Reported first half-year profit of RMB 1.18 billion, primarily due to a one-time release of RMB 1.24 billion in deferred income from the Bayer agreement termination.
Gross margin improved to 54.2% from 46.5% year-over-year, with gross profit up 147% to RMB 117.8 million.
Prescription and patient access expanded, especially in Tier 2 and Tier 3 hospitals, supported by NRDL inclusion.
Advanced post-marketing and real-world studies, including the 2,000-patient BLOOM study, and filed for dorzagliatin registration in Hong Kong.
Financial highlights
Revenue for H1 2025: RMB 217.4 million, up 112% year-over-year; sales volume up 108% to 1,764,000 packs.
Gross profit: RMB 117.8 million, up 147% year-over-year; gross margin: 54.2%.
Net profit for H1 2025: RMB 1.18 billion, mainly from a one-time release of RMB 1.24 billion in deferred income.
Cash and cash equivalents: RMB 1,022.8 million as of June 30, 2025.
Selling expenses as a percentage of revenue dropped significantly, improving operational leverage.
Outlook and guidance
Confident in achieving or exceeding RMB 1 billion in annual sales by 2027, with continued 30-40% annual revenue growth expected.
Focus on expanding commercialization, R&D for dorzagliatin and 2nd generation GKA, and new indications in metabolic disorders.
Plans to increase sales team by 30% and invest in digital platforms and AI for operational efficiency.
Bioequivalence study for dorzagliatin-metformin fixed dose combination planned for early 2026, with product launch anticipated in 2028-2029.
R&D spending expected to rise, leveraging stable sales growth.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Hua Medicine earnings date
H2 202527 Mar, 2026
Next Hua Medicine earnings date
H2 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Hua Medicine is a China-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of metabolic diseases. The company specializes in drug candidates targeting type 2 diabetes and related conditions, leveraging internal research and clinical development capabilities. Hua Medicine conducts both domestic and international clinical trials and collaborates with academic and industry partners to advance its pipeline. The company is headquartered in Shanghai, China, and its shares are listed on the HKEX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage